09:24 AM EDT, 04/29/2025 (MT Newswires) -- Merck ( MRK ) said Tuesday that it has begun construction of $1 billion biologics facility in Wilmington, Delaware.

The laboratory component of the site, which spans 470,000 square feet at the Chestnut Run Innovation & Science Park, is anticipated to be operational by 2028, with investigational compound production beginning in 2030, the company said.

Merck ( MRK ) said it plans to produce its immunotherapy drug Keytruda at the facility for US patients.

The company said it plans to invest $3.5 billion in biologics and small molecule manufacturing facilities in the US over the next four years.